Antiallergic tea catechin, (-)-epigallocatechin-3-O-(3-O-methyl)-gallate, suppresses FcepsilonRI expression in human basophilic KU812 cells. 2002

Yoshinori Fujimura, and Hirofumi Tachibana, and Mari Maeda-Yamamoto, and Toshio Miyase, and Mitsuaki Sano, and Koji Yamada
Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka 812-8581, Japan.

We previously found that the O-methylated derivative of (-)-epigallocatechin-3-O-gallate (EGCg), (-)-epigallocatechin-3-O-(3-O-methyl)-gallate (EGCG' '3Me), has potent antiallergic activity. The high-affinity IgE receptor, FcepsilonRI, is found at high levels on basophils and mast cells and plays a key role in a series of acute and chronic human allergic reactions. To understand the mechanism of action for the antiallergic EGCG' '3Me, the effect of EGCG' '3Me on the cell surface expression of FcepsilonRI in human basophilic KU812 cells was examined. Flow cytometric analysis showed that EGCG' '3Me was able to decrease the cell surface expression of FcepsilonRI. Moreover, immunoblot analysis revealed that total cellular expression of the FcepsilonRI alpha chain decreased upon treatment with EGCG' '3Me. FcepsilonRI is a tetrameric structure comprising one alpha chain, one beta chain, and two gamma chains. The level of mRNA production of each subunit in KU812 cells was investigated. EGCG' '3Me reduced FcepsilonRI alpha and gamma mRNA levels. The cross-linkage of FcepsilonRI causes the activation of basophils, which leads to the secretion of inflammatory mediators including histamine. EGCG' '3Me treatment inhibited the FcepsilonRI cross-linking-induced histamine release. These results suggested that EGCG' '3Me can negatively regulate basophil activation through the suppression of FcepsilonRI expression.

UI MeSH Term Description Entries
D002392 Catechin An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms. Catechinic Acid,Catechuic Acid,(+)-Catechin,(+)-Cyanidanol,(+)-Cyanidanol-3,(-)-Epicatechin,(2R,3R)-2-(3,4-Dihydroxyphenyl)-3,5,7-chromanetriol,2H-1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-, (2R-cis)-,3,3',4',5,7-Flavanpentol,Catergen,Cianidanol,Cyanidanol-3,Epicatechin,KB-53,Z 7300,Zyma,Cyanidanol 3,KB 53,KB53
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006636 Histamine Release The secretion of histamine from mast cell and basophil granules by exocytosis. This can be initiated by a number of factors, all of which involve binding of IgE, cross-linked by antigen, to the mast cell or basophil's Fc receptors. Once released, histamine binds to a number of different target cell receptors and exerts a wide variety of effects. Histamine Liberation,Histamine Liberations,Histamine Releases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001491 Basophils Granular leukocytes characterized by a relatively pale-staining, lobate nucleus and cytoplasm containing coarse dark-staining granules of variable size and stainable by basic dyes. Basophil
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013662 Tea The infusion of leaves of CAMELLIA SINENSIS (formerly Thea sinensis) as a beverage, the familiar Asian tea, which contains CATECHIN (especially epigallocatechin gallate) and CAFFEINE. Black Tea,Green Tea,Black Teas,Green Teas,Tea, Black,Tea, Green,Teas, Black,Teas, Green
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions
D017455 Receptors, IgE Specific molecular sites on the surface of B- and T-lymphocytes which combine with IgEs. Two subclasses exist: low affinity receptors (Fc epsilon RII) and high affinity receptors (Fc epsilon RI). Antigens, CD23,CD23 Antigens,Fc Receptors, epsilon,Fc epsilon Receptor,Fc epsilon Receptors,IgE Receptor,IgE Receptors,Receptors, Fc epsilon,epsilon Fc Receptor,epsilon Fc Receptors,CD 23 Antigens,CD23 Antigen,Fc epsilon RI,Fc epsilon RII,Immunoglobulin E Receptor,Antigen, CD23,Antigens, CD 23,Fc Receptor, epsilon,Receptor, Fc epsilon,Receptor, IgE,Receptor, Immunoglobulin E,Receptor, epsilon Fc,Receptors, epsilon Fc,epsilon RI, Fc,epsilon RII, Fc,epsilon Receptor, Fc,epsilon Receptors, Fc
D018926 Anti-Allergic Agents Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) Anti-Allergic,Anti-Allergic Agent,Anti-Allergy Drug,Antiallergic,Antiallergic Agent,Antiallergic Drug,Anti-Allergics,Anti-Allergy Drugs,Antiallergic Agents,Antiallergic Drugs,Antiallergics,Antiallergy Agents,Agent, Anti-Allergic,Agent, Antiallergic,Agents, Anti-Allergic,Agents, Antiallergic,Agents, Antiallergy,Anti Allergic,Anti Allergic Agent,Anti Allergic Agents,Anti Allergics,Anti Allergy Drug,Anti Allergy Drugs,Drug, Anti-Allergy,Drug, Antiallergic,Drugs, Anti-Allergy,Drugs, Antiallergic

Related Publications

Yoshinori Fujimura, and Hirofumi Tachibana, and Mari Maeda-Yamamoto, and Toshio Miyase, and Mitsuaki Sano, and Koji Yamada
October 2009, Journal of agricultural and food chemistry,
Yoshinori Fujimura, and Hirofumi Tachibana, and Mari Maeda-Yamamoto, and Toshio Miyase, and Mitsuaki Sano, and Koji Yamada
January 2004, BioFactors (Oxford, England),
Yoshinori Fujimura, and Hirofumi Tachibana, and Mari Maeda-Yamamoto, and Toshio Miyase, and Mitsuaki Sano, and Koji Yamada
October 2009, Free radical biology & medicine,
Yoshinori Fujimura, and Hirofumi Tachibana, and Mari Maeda-Yamamoto, and Toshio Miyase, and Mitsuaki Sano, and Koji Yamada
May 2019, Journal of agricultural and food chemistry,
Yoshinori Fujimura, and Hirofumi Tachibana, and Mari Maeda-Yamamoto, and Toshio Miyase, and Mitsuaki Sano, and Koji Yamada
February 2000, Bioscience, biotechnology, and biochemistry,
Yoshinori Fujimura, and Hirofumi Tachibana, and Mari Maeda-Yamamoto, and Toshio Miyase, and Mitsuaki Sano, and Koji Yamada
April 2020, Biomolecules,
Yoshinori Fujimura, and Hirofumi Tachibana, and Mari Maeda-Yamamoto, and Toshio Miyase, and Mitsuaki Sano, and Koji Yamada
March 2011, Antimicrobial agents and chemotherapy,
Yoshinori Fujimura, and Hirofumi Tachibana, and Mari Maeda-Yamamoto, and Toshio Miyase, and Mitsuaki Sano, and Koji Yamada
March 2005, Journal of agricultural and food chemistry,
Yoshinori Fujimura, and Hirofumi Tachibana, and Mari Maeda-Yamamoto, and Toshio Miyase, and Mitsuaki Sano, and Koji Yamada
December 1997, Journal of nutritional science and vitaminology,
Yoshinori Fujimura, and Hirofumi Tachibana, and Mari Maeda-Yamamoto, and Toshio Miyase, and Mitsuaki Sano, and Koji Yamada
September 2016, Molecules (Basel, Switzerland),
Copied contents to your clipboard!